Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 1999

View Archived Issues

Vivus ends license agreement for gene therapy treatment for erectile dysfunction

Company Profile: Biopure

Acetylcholine releaser SM-21 improves cognitive functions in rats and mice

Intravenous zanamivir offers potential against influenza A

New naturally occurring hepatoprotective/immunostimulating compound from Il Yang in phase II

Roche to submit sNDA for Xeloda as first-line colorectal cancer therapy

Vitrix soon to enter expanded clinical development

Allosteric adenosine receptor modulators described by Medco

Potent and selective, optically active alpha1-adrenoceptor ligands developed in Taiwan

Recently issued U.S. patent covers Searle's newest p38 MAP kinase inhibitors

Agents for allergic diseases in development by Dainippon Ink & Chemicals

Phthalazinones synthesized at Byk Gulden specifically inhibit PDE4

New triazoles from SSP display excellent antifungal activity in preliminary tests

Important market launch for Ziagen

IPA: a potent endogenous antioxidant and neuroprotective agent

Health Canada approves new type II diabetes treatment from Novo Nordisk

Arava approved in Europe for rheumatoid arthritis

U.S. and Canadian academics design novel prodrug approach to 5-FU chemotherapy

Fujisawa seeks approval for tacrolimus ointment in the U.S.

AstraZeneca launches new Zomig formulation for migraine

Huperzine A improves cognition in Chinese adolescent students

NovoRapid approved in E.U. for treatment of diabetes

Wider therapeutic index predicted for Ditropan XL compared to conventional Ditropan

Health Canada grants priority review status for new flu pill

Potential new treatment for Friedreich's ataxia: idebenone

Access initiates clinical trial of OraDisc for amlexanox delivery